Travel Stocks Fall on Worries Meta's Muse May Eat Their Lunch -- Barrons.com
Dow Jones2026/09/22 17:39By Anita Hamilton
The buzzy release of Meta's artificial intelligence personal assistant Muse earlier this month has been good for Meta stock, which has surged more than 20% since its announcement. But other stocks are feeling the pain, namely travel companies whose bread and butter is booking flights and places to stay on vacation-something Muse can now do too.
Shares of Expedia, Booking Holdings, TripAdvisor and AirBnb were all falling Tuesday, with Expedia seeing the biggest drop of 5.5% to $265.60 by midday.
The stock drops coincide with the Muse app topping the list of free apps in Apple's App store on Tuesday.
A new report from Bloomberg Intelligence lays out the problem for travel companies. Analysts Mandeep Singh and William Tong argue that if agents such as Muse siphon off just 5% to 10% of their business, along with that of ride-sharing and delivery firms, their combined revenue loss could exceed $5 billion. "Marketplaces could face lower direct traffic, new distribution costs and weaker customer ownership, while agent providers and mobile operating system owners gain leverage over discovery and transactions," the analysts added.
Muse isn't the only AI personal agent that could eat into travel sites lunch either. Instinct, a text-based rival from privately-held Spear Street, launched this summer. Paypal and Stripe are also developing agentic payment systems, while Mastercard and Visa have partnered with Alchemy to do so much the same.
Write to Anita Hamilton at anita.hamilton@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
September 22, 2026 13:39 ET (17:39 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
